DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15290.0
(0.53%)
KRW 15290.0
(0.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 730.99 Billion KRW | 10.48% |
| 2022 | 661.64 Billion KRW | 11.35% |
| 2021 | 594.19 Billion KRW | 6.28% |
| 2020 | 559.1 Billion KRW | 15.93% |
| 2019 | 482.28 Billion KRW | 20.33% |
| 2018 | 400.8 Billion KRW | 12.98% |
| 2017 | 354.76 Billion KRW | 14.56% |
| 2016 | 309.69 Billion KRW | 19.14% |
| 2015 | 259.92 Billion KRW | 15.01% |
| 2014 | 226.01 Billion KRW | 6.07% |
| 2013 | 213.08 Billion KRW | 18.19% |
| 2012 | 180.29 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 203.53 Billion KRW | 3.41% |
| 2024 Q1 | 196.82 Billion KRW | 4.76% |
| 2023 Q2 | 185.87 Billion KRW | 2.81% |
| 2023 FY | 730.99 Billion KRW | 10.48% |
| 2023 Q4 | 187.87 Billion KRW | 6.48% |
| 2023 Q3 | 176.43 Billion KRW | -5.08% |
| 2023 Q1 | 180.8 Billion KRW | 8.64% |
| 2022 Q4 | 166.42 Billion KRW | 4.22% |
| 2022 Q3 | 159.68 Billion KRW | -5.99% |
| 2022 Q2 | 169.85 Billion KRW | 2.52% |
| 2022 Q1 | 165.67 Billion KRW | 10.07% |
| 2022 FY | 661.64 Billion KRW | 11.35% |
| 2021 Q2 | 154.76 Billion KRW | 7.55% |
| 2021 Q1 | 143.89 Billion KRW | 1.29% |
| 2021 Q4 | 150.52 Billion KRW | 3.8% |
| 2021 Q3 | 145.01 Billion KRW | -6.3% |
| 2021 FY | 594.19 Billion KRW | 6.28% |
| 2020 Q2 | 138.79 Billion KRW | 6.27% |
| 2020 Q4 | 142.06 Billion KRW | -3.77% |
| 2020 FY | 559.1 Billion KRW | 15.93% |
| 2020 Q1 | 130.6 Billion KRW | 2.32% |
| 2020 Q3 | 147.63 Billion KRW | 6.36% |
| 2019 Q2 | 120.71 Billion KRW | 9.25% |
| 2019 FY | 482.28 Billion KRW | 20.33% |
| 2019 Q1 | 110.49 Billion KRW | 8.76% |
| 2019 Q4 | 127.65 Billion KRW | 3.43% |
| 2019 Q3 | 123.41 Billion KRW | 2.23% |
| 2018 Q2 | 103 Billion KRW | 11.09% |
| 2018 Q4 | 101.6 Billion KRW | -1.81% |
| 2018 Q3 | 103.47 Billion KRW | 0.46% |
| 2018 FY | 400.8 Billion KRW | 12.98% |
| 2018 Q1 | 92.72 Billion KRW | 0.14% |
| 2017 Q1 | 80.58 Billion KRW | 0.58% |
| 2017 Q4 | 92.59 Billion KRW | 2.81% |
| 2017 Q3 | 90.06 Billion KRW | -1.6% |
| 2017 Q2 | 91.52 Billion KRW | 13.58% |
| 2017 FY | 354.76 Billion KRW | 14.56% |
| 2016 FY | 309.69 Billion KRW | 19.14% |
| 2016 Q2 | 81.24 Billion KRW | 16.19% |
| 2016 Q1 | 69.92 Billion KRW | -3.47% |
| 2016 Q4 | 80.11 Billion KRW | 2.19% |
| 2016 Q3 | 78.4 Billion KRW | -3.5% |
| 2015 Q2 | 63.65 Billion KRW | 16.42% |
| 2015 Q1 | 54.68 Billion KRW | -4.52% |
| 2015 Q3 | 69.15 Billion KRW | 8.63% |
| 2015 Q4 | 72.43 Billion KRW | 4.75% |
| 2015 FY | 259.92 Billion KRW | 15.01% |
| 2014 Q3 | 59.07 Billion KRW | 3.33% |
| 2014 Q4 | 57.27 Billion KRW | -3.05% |
| 2014 FY | 226.01 Billion KRW | 6.07% |
| 2014 Q1 | 52.49 Billion KRW | -5.66% |
| 2014 Q2 | 57.17 Billion KRW | 8.9% |
| 2013 Q4 | 55.64 Billion KRW | 0.64% |
| 2013 FY | 213.08 Billion KRW | 18.19% |
| 2013 Q1 | 47.49 Billion KRW | -2.87% |
| 2013 Q2 | 54.65 Billion KRW | 15.08% |
| 2013 Q3 | 55.29 Billion KRW | 1.18% |
| 2012 FY | 180.29 Billion KRW | 0.0% |
| 2012 Q4 | 48.89 Billion KRW | -3.47% |
| 2012 Q3 | 50.65 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | -437.682% |
| CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | -678.426% |
| Celltrion Pharm, Inc. | 388.79 Billion KRW | -88.015% |
| Huons Global Co., Ltd. | 758.37 Billion KRW | 3.611% |
| Enzychem Lifesciences Corporation | 76.03 Billion KRW | -861.342% |
| Humedix Co., Ltd. | 152.27 Billion KRW | -380.052% |
| Boditech Med Inc. | 134.21 Billion KRW | -444.627% |
| EuBiologics Co., Ltd. | 69.36 Billion KRW | -953.826% |
| FutureChem Co.,Ltd | 13.96 Billion KRW | -5133.339% |
| Huons Co., Ltd. | 552 Billion KRW | -32.425% |
| BNC Korea Co., Ltd. | 80.99 Billion KRW | -802.489% |
| AptaBio Therapeutics Inc. | 323.86 Million KRW | -225606.693% |